Investigating COVID19 related brain hypoxia using near infra-red spectroscopy (NIRS).
Summary
COVID-19 infection have been linked with changes in brain function in some individuals. It is unknown if these changes in brain function last a short time or are long-lasting. This study will use near-infrared spectroscopy (NIRS) a technique that uses low intensity light to measure brain oxygen and function in people who have had COVID-19. We will compare brain oxygen and function data from people who have had COVID-19 to people who have not had the COVID-19 infection.
NIRS is a non-invasive imaging technique that has no risk of side effects or complications. We plan to use NIRS to better understand changes in brain function following COVID-19.
Eligibility
Eligible gender: Male, Female
Eligible ages: 18 to 90
Accepts healthy participants: Yes
Inclusion criteria:
Age ≥18 and can give informed consent.
Men and women
Eligibility criteria for participants with lingering COVID-19 symptoms
1) Medical diagnosis of COVID-19
2) Not having returned to pre-COVID-19 level of health and function after 2 up to 6 months
3) Having at least 2 symptoms that suggest long COVID (see list below)
• Fatigue
• Shortness of breath/ dyspnea
• Joint pain
• Chest pain
• Body aches
• Difficulty concentrating
• Muscle weakness/ Inability to exercise
• Headache
• Difficulty sleeping
• Anosmia/ inability to smell
• Brain Fog/ difficulty with memory and concentration
4) Non-smoker (nicotine or Marijuana)
5) No history of cardiovascular/vascular disease
No history of other systemic inflammatory disease like inflammatory bowel syndrome, asthma, autoimmune diseases, coeliac disease, glomerulonephritis, and hepatitis.
6) No other neuropsychological condition
Eligibility criteria without lingering COVID-19 symptoms
1) Medical diagnosis of COVID-19
2) Non-smoker (nicotine or Marijuana)
3) No history of cardiovascular/vascular disease
4) No history of other systemic inflammatory disease like inflammatory bowel syndrome, asthma, autoimmune diseases, coeliac disease, glomerulonephritis, and hepatitis.
5) No neuropsychological condition
Selection criteria Controls:
1) Non-smoker (nicotine or Marijuana)
2) No history of cardiovascular/vascular disease
3) No history of other systemic inflammatory disease like inflammatory bowel syndrome, asthma, autoimmune diseases, coeliac disease, glomerulonephritis, and hepatitis.
4) No neuropsychological condition
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Dr Damilola D. Adingupu Research Associate Dunn Lab, Department of Radiology Cummings School of Medicine 3330 Hospital Drive NW Calgary, AB, Canada T2N 4N1
Principal investigator:
Jeffrey Dunn
Clinical trial:
No
REB-ID:
REB21-0907